GSK announces start of Phase lll programme for mepolizumab in severe refractory asthma

GlaxoSmithKlineGlaxoSmithKline plc (GSK) has announced the start of a Phase III programme to evaluate the efficacy and safety of mepolizumab, an investigational IL-5 antagonist, as adjunctive therapy in severe uncontrolled refractory asthma. The Phase III programme includes two key studies:
  • MEA115588: A 32-week multicentre, randomised, double-blind, double-dummy, placebo-controlled study in patients with severe uncontrolled refractory asthma. The primary endpoint of the study is to evaluate the efficacy of mepolizumab 75 mg intravenous (i.v.) and 100 mg subcutaneous (SC) every 4 weeks versus placebo on the frequency of clinically significant exacerbations in patients with severe refractory asthma.
  • MEA115575: A 24-week randomised, double-blind, placebo-controlled, parallel-group, multicentre study to evaluate the use of mepolizumab 100mg subcutaneous adjunctive therapy every 4 weeks to reduce steroid use in patients with severe refractory asthma.

The Phase III programme also includes safety extension trials that will further assess treatment of subsequent asthma attacks in mepolizumab-naive as well as previously-treated patients.

"The progression of this Phase III programme represents a significant milestone in the clinical development of mepolizumab as a potential treatment option for patients with severe uncontrolled refractory asthma," commented Steve Yancey, Vice-President and Head of the mepolizumab development team.

About mepolizumab
Mepolizumab is an investigational fully humanised IgG monoclonal antibody specific for interleukin 5 (IL-5) which is in development for severe refractory asthma in patients who exacerbate despite high-dose inhaled (ICS) or oral corticosteroids (OCS) and long-acting beta-2 agonist use. IL-5 is a cytokine which regulates the growth, activation and survival of eosinophils (white blood cells) and provides an essential signal for the movement of eosinophils from the bone marrow into the lung. Mepolizumab binds to human IL-5, stopping it from binding to its receptor on the surface of eosinophils. Inhibiting IL-5 binding in this manner reduces blood, tissue and sputum eosinophil levels, which in turn reduces the frequency of exacerbations. Mepolizumab is not approved for use anywhere in the world.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

Most Popular Now

Primary endpoint met in COMET-TAIL Phase III trial…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Vir) (Nasdaq: VIR) announced headline data from the randomised, multi-centre, open-label COMET-TAIL Phase...

Merck and Ridgeback's molnupiravir, an oral COVID-…

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Re...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Two billion doses of AstraZeneca’s COVID-19 vaccin…

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the l...

Pfizer's novel COVID-19 oral antiviral treatment c…

Pfizer Inc. (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on a...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

Repurposing a familiar drug for COVID-19

For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day...

Researchers reveal a strategy for next-generation …

A study led by the Garvan Institute of Medical Research has revealed a guide to developing COVID-19 vaccines that both prevent the coronavirus from infecting human cells ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...

A commonly found parasite could treat certain type…

Scientists have discovered that a deadly parasite, known to cause ill health in pregnant women and immunocompromised patients, could potentially be used to treat various ...